Cargando…
SAT-141 Glycoprotein NMB (GPNMB) Is Pro-Tumorigenic in TSC2-Null Cancer Cells and Is a Potential Drug Target and Biomarker for Lymphangioleiomyomatosis (LAM)
Lymphangioleiomyomatosis (LAM) is an estrogen-sensitive lung disease found almost exclusively in women that is characterized by hyperproliferation of smooth muscle cells forming small tumors, or LAM lesions throughout the lungs of patients. Growth of these tumors leads to progressive loss of pulmona...
Autores principales: | Gibbons, Erin, Taya, Manisha, Seger, Christina, Hammes, Stephen R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207399/ http://dx.doi.org/10.1210/jendso/bvaa046.1386 |
Ejemplares similares
-
RF19 | PSUN351 Glycoprotein-NMB (GPNMB) is Pro-Tumorigenic in Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2022) -
THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
por: Gibbons, Erin, et al.
Publicado: (2023) -
OR34-5 Infiltrating Neutrophils and Neutrophil Elastase (NE) Promote Tumor Growth in a Mouse Model for Lymphangioleiomyomatosis (LAM)
por: Taya, Manisha, et al.
Publicado: (2019) -
Estradiol Augments the Production and Actions of Polymorphonuclear Cells to Promote Lymphangioleiomyomatosis (LAM) Progression
por: Minor, Briaunna M N, et al.
Publicado: (2021) -
SUN-134 Estrogen Induces Granulocytic Myeloid Derived Suppressor Cell Production to Potentially Modulate Lymphangioleiomyomatosis (LAM) Tumor Progression
por: Minor, Briaunna, et al.
Publicado: (2020)